Eplerenone May Reach Market Before Pfizer Merger: Co-Promotion Planned
Executive Summary
Pfizer and Pharmacia may co-promote the selective aldosterone blocker eplerenone for hypertension by the end of this year if FDA approval for the product precedes the pending merger between the firms
You may also be interested in...
Pfizer/Pharmacia Sales Force Debuts In June; Inspra Launch Delayed
The restructured Pfizer/Pharmacia sales force will begin operations in June
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011